Ding Dong is the Skinny Label (Effectively) Dead?
FDA Law Blog
SEPTEMBER 6, 2021
Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. The catch is, as we have learned from the GSK v. Until recently, there hasn’t been a need for such a safe harbor, as Courts have not found inducement to infringe in this context, but the GSK v.
52 
Let's personalize your content